In New Zealand, from November 1, 2017, Ozurdex (dexamethasone implants) will be funded for eligible people with diabetic macular edema (DMO), a serious complication of type 1 and type 2 diabetes that can cause blindness if untreated.
YOUR SOURCE FOR THE BEST ASSISTIVE TECH NEWS, REVIEWS AND INTERVIEWS FROM TOP BLIND AND LOW VISION EXPERTS. AN ENTERTAINING AND TRUSTWORTHY DISCUSSION ON EMERGING TECHNOLOGIES
You must be logged in to post a comment.